Eczema
PLAY VIDEOEczema is a chronic skin condition affecting one in five children in the UK and one in ten adults. In the form of contact dermatitis, eczema accounts for 84 - 90% of all occupational skin diseases¹.
Those with eczema experience dry, intensely itchy, inflamed, and often painful skin. Half of patients with eczema in the form of moderate to severe atopic dermatitis indicate that it significantly limits their lifestyle, with sleep disruption a common occurrence for both adults and children. The long-term impact of eczema can result in deteriorated mental health conditions and a higher risk of depression2.
While current treatments for eczema often rely on topical steroids, these can lead to skin thinning and resistance, which can make them unsuitable for prolonged use. In addition, patients can experience painful withdrawal symptoms when the use of topical steroids is discontinued3.

At Derma Biosciences, we’re formulating a plant-derived alternative that provides deep hydration while actively reducing inflammation at the source to reduce the appearance and discomfort of eczema. Developed by nature, validated by science.
Eczema Treatment in Development Phase
ECZ-001 - Eczema Treatment (Paediatric & Adult Eczema)
Read more
Specialisation
Resources
- Our skin and eczema – National Eczema Society (2021). https://eczema.org/information-and-advice/our-skin-and-eczema/.
- National Eczema Association (2025) Eczema Statistics | National Eczema Association. https://nationaleczema.org/eczema-facts/.
- Mohta, A. and Sathe, N.C. (2024) Topical steroid withdrawal (Red skin syndrome). https://www.ncbi.nlm.nih.gov/books/NBK603718/.











